SEC Form 4 · accession 0001209191-18-059976
SANGAMO THERAPEUTICS, INC · SGMO
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Stephane Boissel
Officer — EVP, Corporate Strategy
Period of report
Nov 23, 2018
Accepted (ET)
Nov 26, 2018 · 9:11 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001001233
Table I — non-derivative securities
No Table I lines on this filing.
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F1,F2 | $11.08 | Nov 23, 2018 | A | 283,523 | A | — | Nov 22, 2028 | Common Stock | 283,523 | 283,523 | D |
Explanation of responses
- F1Includes 68,523 option shares granted to the Reporting Person pursuant to the July 20, 2018 Share Purchase Agreement between the Issuer and certain shareholders of TxCell S.A. and 215,000 option shares granted pursuant to the Reporting Person's October 2, 2018 employment agreement with the Issuer.
- F2One-quarter (1/4) of the option shares vest and become exercisable after one (1) year measured from the November 23, 2018 grant date, and the remainder of the option shares will vest and become exercisable in equal monthly installments for thirty-six (36) months thereafter, provided that the Reporting Person remains in service with the Issuer through each such monthly vesting date.